Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870552 | 0.93 | KCNH2 (0.66) | KCNH2HRH1HTR2AHTR2CDRD2 | |
| SCHEMBL13870535 | 0.90 | KCNH2 (0.56) | KCNH2HRH1PTAFR | |
| SCHEMBL13964319 | 0.89 | KCNH2 (0.77) | KCNH2HRH1HTR2AHTR2CDRD2 | |
| SCHEMBL13870485 | 0.88 | KCNH2 (0.81) | KCNH2HRH1HTR2AHTR2CDRD2 | |
| SCHEMBL14318737 | 0.86 | KCNH2 (0.67) | KCNH2HRH1HTR2AHTR2CDRD2 | |
| SCHEMBL13870533 | 0.83 | KCNH2 (0.47) | KCNH2HRH1TBXA2RLMNA | |
| SCHEMBL13870560 | 0.83 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL13870501 | 0.83 | KCNH2 (0.82) | KCNH2HRH1HTR2AHTR2CDRD2 | |
| SCHEMBL13939616 | 0.82 | KCNH2 (0.70) | KCNH2HRH1HTR2AHTR2CDRD2 | |
| SCHEMBL13870567 | 0.82 | KCNH2 (0.60) | KCNH2HRH1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7411069-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7326721-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |